Waverley Pharma Inc. is a biopharmaceutical company focused on developing oncology therapeutics in the UK. The company faces significant concerns, including a low market cap of $540K and a concerning financial health score of 16/100, indicating poor profitability with a net margin of -45.7% and low liquidity ratios (current ratio of 0.09). While it has a gross margin of 35.6%, the overall financial metrics suggest challenges in sustaining operations and growth, raising red flags for potential investors.
Loading financial metrics...
Company has $45K in cash but burned $132K last quarter. At this burn rate, only 0.3 quarters of runway remain without additional financing.
Company posted a loss of $-872K over the last year, representing 32.0% of revenue.
Debt of $3.6M is 80.0x the company's cash position of $45K.
Operating cash flow has been negative for 3 consecutive quarters, burning $528K over the last year.
Exceptional revenue growth of 121.8% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 21.4pp, demonstrating strong operational leverage.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q2 (June 30, 2026)